Percheron Therapeutics Limited (PERCF)
Market Closed
10 Aug, 20:00
OTC PINK OTC PINK Primary $
0. 00
0
0%
$
3.65M Market Cap
- P/E Ratio
- Div Yield
55,000 Volume
0 Eps
$ 0
Previous Close Want to track PERCF and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
PERCF closed yesterday higher at $0, an increase of 0% from Friday's close, completing a monthly decrease of -15.1943% or $0. Over the past 12 months, PERCF stock lost -52%.
PERCF is not paying dividends to its shareholders.
The last earnings report, released on Feb 17, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
Percheron Therapeutics Limited has completed 1 stock splits, with the recent split occurring on Nov 06, 2013.
The company's stock is traded on one exchange.
Percheron Therapeutics Limited (PERCF) FAQ
What is the stock price today?
The current price is $0.00.
On which exchange is it traded?
Percheron Therapeutics Limited is listed on OTC PINK.
What is its stock symbol?
The ticker symbol is PERCF.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 3.65M.
Has Percheron Therapeutics Limited ever had a stock split?
Percheron Therapeutics Limited had 1 splits and the recent split was on Nov 06, 2013.
Percheron Therapeutics Limited Profile
| Biotechnology Industry | Healthcare Sector | James Stuart Garner CEO | OTC PINK Exchange | AU0000317281 ISIN |
| AU Country | 8 Employees | - Last Dividend | 6 Nov 2013 Last Split | - IPO Date |
Percheron Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals for cancer and rare diseases in Australia. The company's lead asset is ATL1102, an antisense oligonucleotide inhibitor of CD49d, which is in Phase IIb clinical trial for the treatment of Duchenne muscular dystrophy, multiple sclerosis, asthma, and other inflammatory indications. It also develops HMBD-002, a recombinant humanised monoclonal IgG4 antibody, which completed Phase I clinical trial to targer v-domain immunoglobulin suppressor of T-cell activation and cancer cells. The company was formerly known as Antisense Therapeutics Limited and changed its name to Percheron Therapeutics Limited in December 2023. Percheron Therapeutics Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.
Contact Information
Address: Collins Place
Phone: 61 3 9827 8999
Website: https://www.percherontx.com
